Chairman and CEO Thomas Moore of Advaxis, Inc (ADXS) called into SmallCapVoice.com to go over the business market, model and recent news for the company. Advaxis is a biotechnology company developing the next generation of immunotherapies for cancer and infectious diseases. Advaxis immunotherapies are based on a novel platform technology using live, attenuated bacteria that are bio-engineered to secrete an antigen/adjuvant fusion protein that redirects the powerful immune response all human beings have to the bacteria to the cancer itself.
ADXS-HPV, Advaxis’ first construct is being evaluated in 4 Phase 2 clinical trials for HPV associated diseases (CIN 2/3, cervical cancer, and head & neck cancer). ADXS-HER2 is being evaluated for canine osteosarcoma in companion dogs. Over fifteen (15) distinct constructs are in various stages of development, either developed directly by the Company or through strategic collaborations with recognized centers of excellence such as: the National Cancer Institute, Cancer Research – UK, the Wistar Institute, the University of Pennsylvania, among others.